Landscape Capital Management L.L.C. Sells 56,516 Shares of Guardant Health, Inc. $GH

Landscape Capital Management L.L.C. decreased its position in Guardant Health, Inc. (NASDAQ:GH) by 73.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 20,085 shares of the company’s stock after selling 56,516 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Guardant Health were worth $2,051,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after buying an additional 435,232 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Guardant Health by 3.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Guardant Health by 14.4% in the 4th quarter. Federated Hermes Inc. now owns 2,031,562 shares of the company’s stock valued at $207,504,000 after buying an additional 255,193 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In other news, insider John G. Saia sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares in the company, valued at $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the transaction, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 449,238 shares of company stock valued at $51,164,492. 5.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Barclays boosted their price target on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Stifel Nicolaus upped their target price on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. upped their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Wells Fargo & Company upped their target price on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Stock Down 1.4%

Shares of Guardant Health stock opened at $129.82 on Tuesday. The stock has a market capitalization of $17.21 billion, a P/E ratio of -38.29 and a beta of 1.61. The stock has a 50 day moving average price of $104.23 and a two-hundred day moving average price of $102.22. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $135.00.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.